CTOR
Citius Oncology, Inc.NASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$58.26M
P/E Ratio
—
EPS
$-0.32
Beta
3.43
52W High
$6.19
52W Low
$0.49
50-Day MA
$0.96
200-Day MA
$1.59
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
35.59
PEG Ratio
—
About Citius Oncology, Inc.
Citius Oncology, Inc. is a clinical-stage biopharmaceutical firm committed to the development of groundbreaking cancer therapies tailored for underserved populations. The company boasts a promising pipeline that utilizes proprietary technologies to create innovative treatments aimed at various cancer indications, enhancing both efficacy and safety. Through strategic partnerships and a dedication to thorough clinical research, Citius Oncology is well-positioned for significant growth as it navigates crucial clinical trial phases and regulatory pathways, with the ultimate goal of improving patient outcomes in oncology.
Fundamentals
| Revenue (TTM) | $3.94M |
| Gross Profit (TTM) | $3.15M |
| EBITDA | — |
| Operating Margin | -133.20% |
| Return on Equity | -47.40% |
| Return on Assets | -14.00% |
| Revenue/Share (TTM) | $0.05 |
| Book Value | $0.69 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 14.77 |
| EV/Revenue | 15.0 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $88.28M |
| Float | $14.13M |
| % Insiders | 83.89% |
| % Institutions | 7.77% |
Historical Volatility
HV 10-Day
141.82%
HV 20-Day
120.19%
HV 30-Day
100.07%
HV 60-Day
79.08%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($6.00 target)
1
Strong BuyData last updated: 4/10/2026